USAQOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
QHSLab, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.32+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $7.38M
- P/E (TTM)
- –
- Dividend yield
- –
QHSLab, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integrated Service Program [Member] | $1.56M | $1.33M | $1.12M | $979.51K | $781.89K | $678.71K | $643.21K | $534.42K | $444.27K | $362.56K | $270.02K | 51.7% | +99.6% |
| Allergy Diagnostic Kit Sales [Member] | $785.38K | $786.97K | $823.11K | $863.73K | $867.48K | $860.83K | $832.99K | $778.04K | $706.83K | $708.16K | $666.60K | 26.0% | -9.5% |
| Immunotherapy Treatment Sales [Member] | $455.59K | $481.50K | $487.76K | $515.33K | $447.73K | $420.32K | $409.32K | $318.16K | $343.22K | $356.04K | $363.18K | 15.1% | +1.8% |
| Training And Other Revenue [Member] | $52.96K | $39.12K | $40.69K | $23.02K | $23.80K | $24.80K | $22.34K | $20.53K | $20.46K | – | $4.65K | 1.8% | +122.5% |
| Shipping and Handling [Member] | $44.16K | $43.34K | $41.67K | $40.42K | $37.13K | $35.90K | $35.89K | $33.16K | $32.80K | $33.41K | $32.34K | 1.5% | +18.9% |
| Subscription Revenue [Member] | $43.81K | $46.39K | $43.73K | $43.40K | $40.35K | $45.44K | $54.52K | $62.40K | $65.50K | $70.11K | $72.20K | 1.5% | +8.6% |
| Clinical Study Revenue [Member] | – | – | $133.65K | $148.50K | $222.75K | – | $133.65K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of QHSLab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.